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Applications of CRISPR for
musculoskeletal research
The ability to edit DNA at the nucleotide level using clustered regularly interspaced short
palindromic repeats (CRISPR) systems is a relatively new investigative tool that is revolutionizing the analysis of many aspects of human health and disease, including orthopaedic
disease. CRISPR, adapted for mammalian cell genome editing from a bacterial defence system, has been shown to be a flexible, programmable, scalable, and easy-to-use gene editing
tool. Recent improvements increase the functionality of CRISPR through the engineering of
specific elements of CRISPR systems, the discovery of new, naturally occurring CRISPR molecules, and modifications that take CRISPR beyond gene editing to the regulation of gene
transcription and the manipulation of RNA. Here, the basics of CRISPR genome editing will
be reviewed, including a description of how it has transformed some aspects of molecular
musculoskeletal research, and will conclude by speculating what the future holds for the use
of CRISPR-related treatments and therapies in clinical orthopaedic practice.
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Article focus

Applications of clustered regularly
interspaced short palindromic repeats
(CRISPR) technologies to musculoskeletal
research.

Key messages

CRISPR systems are in widespread use in
musculoskeletal research.
Applications include gene ‘knock-in’ and
‘knock-out’ cell models and in small and
large vertebrate animal models.
Novel applications and adaptations
extend the functionality of CRISPR.

Strengths and limitations

This study focusses on the growing use of
CRISPR technologies in musculoskeletal
and orthopaedic applications.
This is a rapidly advancing field and information in this review article may become
surpassed by new advances.
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Introduction

At its simplest, genome editing refers to the
ability to permanently alter DNA at the resolution of the nucleotide. Since its discovery
and practical application first with transcription activator-like effector nuclease (TALEN)

systems1,2 and then with clustered regularly interspaced short palindromic repeats
(CRISPR)-Cas9,3,4 DNA editing has become
one of the most powerful experimental
tools available to biologists. The intellectual
origins for genome editing can be traced
back to the foundational years of molecular
biology where the central dogma of molecular biology, first articulated by Crick in the
early 1960s, states that sequential information passes from nucleic acid to protein
in one direction. This means that permanent edits made in DNA have the potential
to alter protein sequences and, therefore,
protein function in predictable ways. While
this makes CRISPR a powerful experimental
and potentially therapeutic tool, the reality
is more interesting. In addition to the
simplest cases where genes (and therefore
proteins) are altered at the nucleotide levels
or ‘knocked-out’ (KO), there exists an almost
unlimited range of ‘knock-in’ (KI) DNA alterations that can be made. These include the
introduction of fluorescent markers to trace
gene activation, the inclusion of specific mutations to model disease, and the reversible
regulation of gene transcription for probing
developmental processes, to name a few.
Here, we will cover the basics of CRISPR-Cas9
editing and describe the latest developments
in editing as they relate to orthopaedic
biology, including exciting developments
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that expand beyond mouse models to larger, more translationally relevant, animal model systems. Papers were
identified for this review by searching PubMed using
terms that combined “CRISPR”, “CRISPR-Cas9”, “genome
editing”, and “knock-in allele” with orthopaedic-related
terms: “musculoskeletal”, “bone”, “cartilage”, “tendon”,
and “skeletal muscle”.

The origins of CRISPR-Cas9-mediated genome
editing

CRISPR sequences present in the genomes of prokaryotes
and their role as a defence mechanism against bacteriophage infection form the basis of CRISPR-
mediated
genome editing.5 The CRISPR system in Escherichia coli can
be considered a form of adaptive immunity response where
a record of invading bacteriophage is stored and weaponized to destroy future infecting bacteriophage particles.6
The mechanism is clever and sophisticated. Following
bacteriophage infection, bacterial CRISPR-associated (Cas)
proteins cleave the foreign DNA into small fragments and
insert them into defined regions of the E. coli genome.
With sequence information representing phage DNA, the
bacteria now have a record of a prior phage exposure. Upon
re-exposure to a new phage, a Cas nuclease is guided to a
newly invading phage using the captured phage sequence.
The foreign DNA is then cut by the Cas thereby incapacitating the invader. Many different Cas isoforms assembling
distinct CRISPR systems have been described from a diverse
range of bacterial and archaeal genomes and there are
undoubtedly more to be discovered.
However, these clever bacterial defence mechanisms
are not the whole story because bacteriophage have
devised a way to fight back. As part of a type of molecular
‘arms race’, phage have developed a series of anti-CRISPR
strategies.7,8 These can take several forms where some act
to prevent the Cas molecule and wider complex from
binding to DNA and others inhibit the Cas complex from
assembling.9 Researchers have begun to utilize these
molecules to further expand the utility of CRISPR systems
by adding another layer of regulation.10-12

The basics of CRISPR-mediated genome
editing in eukaryotic cells

While three major CRISPR systems have been described
(types I, II, and III), it is the type II CRISPR/Cas system
that has been the main system adapted for mammalian
genome engineering.13 Each system employs the same
basic mechanism of DNA editing but is constituted from a
variety of proteins and isoforms.14 Jinek et al3 first demonstrated that CRISPR could be programmed for targeted
DNA cleavage in vitro, in 2012. The following year,
CRISPR-based genome editing in mammalian cells grown
in culture was described.15,16 The enormous success and
widespread use of CRISPR-based systems is reflected in
the more than 19,000 PubMed articles listed since 2012.
Despite this dominance of type II CRISPR systems, type I
systems are actually more widespread in nature and are

now being explored to expand the CRISPR system repertoire, and more innovations from this class are expected.
Successful gene editing relies on two different DNA
repair pathways in eukaryotic cells: non-
homologous
end joining (NHEJ) and homology-directed repair (HDR)
(Figure 1). Both repair pathways begin the same way with
the CRISPR-Cas9 complex binding to its DNA target as
specified by guide RNA (gRNA; green in Figure 1). The
Cas9 nuclease binds to the RNA scaffold sequence and
cuts DNA with nucleotide level specificity to create a
double-strand break in the DNA sequence. The cellular
DNA repair process then uses one of two mechanisms,
NHEJ or HDR, to repair the double-strand break.
Non-homologous end joining. Following double-strand
cleavage of DNA by Cas nucleases, the dominant repair
process is NHEJ. However, NHEJ is relatively error-prone
and DNA insertions and deletions (indels) in the target
gene occur at the cut site. By adding or removing short
sections of DNA, these indels often result in disruptions
to the reading-frame of the protein coding region leading
to a scrambled protein downstream from the altered sequence. Typically, a premature stop codon occurs downstream of the scrambled sequence and the mutant messenger RNA (mRNA) sequence is degraded via a process
called nonsense-mediated mRNA degradation before the
mutant mRNA can be translated into protein. This results in the so-called gene ‘knock-out’ (KO). Nonsense-
mediated mRNA decay is a major evolutionary backup
plan to minimize the consequences of aberrant protein
production by recognizing the presence of premature
stop codons.17
The three elements required for gene KO by NHEJ are
gRNA sequence specific to target the region to be cut, RNA
scaffold sequence for Cas9 binding, and Cas9 protein for
DNA cleavage. In addition, a protospacer adjacent motif
is required three to four nucleotides downstream from
the region targeted by the gRNA. DNA cleavage will only
occur when the gRNA is adjacent to a protospacer adjacent motif recognition sequence. Note that different Cas
isoforms can have different protospacer adjacent motif
recognition sequences.
These elements can be provided in one or two plasmid
vectors or supplied as a ribonucleoprotein (RNP) complex.
With the plasmid approach, the gRNA and scaffold are
cloned into a plasmid DNA background together with the
Cas9 gene under control of a viral promotor that directs
robust gene expression in mammalian cells. The plasmid(s)
are transfected into target cells and the inclusion of a selectable marker in the plasmid allows the possibility of clonally selecting transfected cells. With the ribonucleoprotein
approach, the gRNA and scaffold sequence is prepared as
RNA and mixed with Cas9 protein to create a RNA-protein
hybrid. This complex is then transfected into cells. Since it
is unknown how efficiently individual gRNA bind to target
sequences, it is common to include several different gRNAs
against the same target gene to maximize editing efficiency. For clinical applications, the adeno-associated virus
BONE & JOINT RESEARCH
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Fig. 1
Basic outline of Cas9 genome editing involving the two major DNA repair pathways: non-homologous end-joining (NHEJ) and homology-directed repair
(HDR). The initial step is for the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 complex to bind to its DNA target. The CRISPR-Cas9
complex comprises Cas9 endonuclease (yellow) and single guide RNA (gRNA) and RNA scaffold (green) that binds to a specific DNA dictated by the gRNA.
DNA cleavage will only occur when the gRNA is adjacent to the protospacer adjacent motif (PAM) recognition sequence. Following double-strand cleavage by
the Cas9 endonuclease, DNA repair can be mediated by one of two possible mechanisms: NHEJ or HDR. Repair by NHEJ (left pathway) leads to the inclusion
of DNA insertions or deletions (orange) resulting in a reading-frame shift, leading to a premature stop codon in the downstream sequence and the ‘knocking-
out’ out of the targeted allele. Repair by HDR (right pathway) in the presence of donor DNA (red) targeted to the cut site results in insertion of the donor DNA
sequence at the site of the DNA strand break and a ‘knock-in’ allele. Image adapted from Cribbs AP, Perera SMW. Science and Bioethics of CRISPR-Cas9 Gene
Editing: An Analysis Towards Separating Facts and Fiction. Yale J Biol Med. 2017;90(4):625–634.

is a Food and Drug Administration (FDA)-approved gene
delivery vehicle where all the CRISPR elements are packed
into viral particles and used to transduce target mammalian cells.18
Homology-directed repair. The HDR process allows the
introduction of an endogenous DNA sequence at the site
of the Cas9-mediated DNA double-strand break. If a segment of donor DNA is provided at the time of DNA cleavage, the host cell incorporates the introduced DNA into
the cut site to create a ‘knock-in’ (KI) allele. The presence
of homology arms designed to anneal to at least 1 kB of
sequence either side of the cut site ensures DNA recombination and efficient homology-directed repair. The ability
to KI exogenous DNA sequence is a particularly exciting
advance because there is an endless variety of modifications that can be introduced including reporter sequences, specific mutations, or modified sequences (such as
loxP/FRT sites) for tissue or temporal control of gene deletion. While the efficiency of genome modification by HDR
is much less than that of NHEJ, HDR allows the creation of
a variety of modifications with unprecedented speed and
specificity than was previously possible.

Recent advances in CRISPR systems

The design of CRISPR genome editing systems is straightforward and within the reach of most molecular biology
VOL. 9, NO. 7, JULY 2020

laboratories with many of the reagents available commercially. Basic laboratory equipment, such as polymerase
chain reaction (PCR) machines, DNA gel running and
visualization equipment, and tissue culture facilities, is
required. Advances occur on a regular basis that increase
the functionality of CRISPR through the engineering of
specific elements of CRISPR systems to the discovery of
new CRISPR systems in different prokaryotic species.
Some of the key improvements are shown in Figure 2 and
described in the following section.
High fidelity Cas9 isoforms. The incidence of unintended
edits is a major concern for CRISPR-Cas9 genome editing.15,19 This refers to the rate of off-target edits due to the
gRNA binding to closely related sequences in the genome
besides the intended target. Estimations of off-
target
effects vary but appear to be dependent on individual gRNAs and the Cas nuclease isoform used. This area is under
intense investigation. Since the intention is to use CRISPR
for human therapies, safety is a paramount consideration.
The original spCas9(1.1) (Streptococcus pyogenes Cas9)
nuclease used in genome editing was found to have detectable unintended edits.15,20 Attempts have been made
in recent years to rationally design better Cas isoforms
by examining the 3D structure of Cas and defining the
molecular points of contact it makes with DNA targets.
These have led to a proliferation of spCas9 variants with
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Fig. 2
Recent advances in clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9. The CRISPR-Cas9 system and its ability to target specific genomic
loci has been adapted for a range of new applications. These include improvements to the Cas9 nuclease itself (A), active or inactive Cas9 fused to different
protein modules for enhanced functionality (B, D, and E), and Cas isoforms that have high affinity for RNA instead of DNA (C). These advances have been
applied to all the musculoskeletal tissues including cartilage, bone, and muscle.

very low off-
target effects including enhanced-
Cas9,21
22
23
HF1-Cas9, and HiFi-Cas9.
Compact Cas9 orthologues. Multiple Cas9 orthologues
have been identified with different properties compared to the spCas9 workhorse. Many of these are
smaller than spCas9 and more easily packaged into viral vectors such as adeno-associated virus, which have
limited cargo-
carrying capacity.18 For example, Cas9
from Staphylococcus aureus (SaCas9) has similar editing
efficiencies to spCas9 but is 350 amino acids smaller and
therefore more easily packaged into delivery vectors.24
Similarly, CasX and CasY25,26 are smaller than spCas9. In
addition, since they were isolated from archaeal bacterial species not normally pathogenic to humans, there
should be no adaptive immune response that may be an
issue for other Cas9 isoforms isolated from S. aureus, for
example.27
Several Cas9 molecules have been identified that
utilize different protospacer adjacent motif recognition
sequences. For example, Cpf1 (Cas12a) is found in a
widespread array of bacterial species and has a different
(T-rich) protospacer adjacent motif recognition sequence
compared to the (G-rich) Cas9 protospacer adjacent motif
sequence.28 In addition, Cpf1 cuts in a staggered pattern
allowing the possibility of directional gene transfer via
HDR. Off-target effects are also reported to be lower in
Cpf1 compared to spCas9.29,30
Base editing using CRISPR. Several CRISPR systems have
been identified that do not use NHEJ or HDR but instead
change individual bases without cutting the nucleic acid
strand.31 The basis of this approach is the use of dead or
catalytically inactive Cas9 (dCas9) fused to a cytidine
deaminase enzyme that retains the ability to be reprogrammed with a gRNA. The fusion does not cut DNA but

instead mediates the conversion of cytidine to uridine,
thereby creating a C to G, or G to A base substitution.
Several new refinements to the base editing approach
have been developed that expand usefulness with fewer
off-target effects,32 expanded protospacer adjacent motif
specificities,33 and the development of more efficient editing variants.34,35
Prime CRISPR-Cas9. Late in 2019, a novel approach was
described called ‘prime editing’, which promises to have
fewer shortcomings and correct a large proportion of
known pathogenic variants in humans.36 Prime editing,
derived from base editing described above, differs from
conventional CRISPR editing in two ways. A modified
Cas9 nickase fused to reverse transcriptase cuts only one
strand of the double-stranded target sequence instead of
cutting both strands as conventional Cas9 does. Then a
gRNA, which contains the sequence to be introduced, is
added to the genome at the nicked site and inserted using
the reverse transcriptase module attached to the modified
Cas9 protein. Importantly, since only one strand is cut
the technique promises to have fewer off-target effects. In
general, prime editing is more precise and versatile than
base editing. The extent to which prime editing will be
useful remains to be determined but this is an exciting development in a field littered with significant discoveries.
RNA-binding Cas isoforms. CRISPR is a system that can
be programmed to target specific stretches of the genome and to edit DNA via the Cas9 endonuclease at precise locations. Within the past two years, several RNA-
binding Cas proteins have been identified that function
to cleave single-stranded RNA molecules such as mRNA,
rather than DNA. Cas13a (also named c2c2)37 utilizes
the same gRNA system employed by Cas9-mediated
editing but the RNA-
Cas isoforms share no protein
BONE & JOINT RESEARCH
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homology with DNA-Cas versions. Interestingly, unlike
Cas9 systems where following cleavage the enzyme
reverts to an inactive state, Cas13a retains enzymatic activity and becomes a non-specific ribonuclease.37
RNA-
binding Cas riboendonucleases have expanded
the functionality of CRISPR systems and have been used
for RNA knockdown applications and adapted for pathogen detection.37,38
CRISPR-mediated epigenetic control. The targeting capacity of CRISPR system has been used to activate and repress gene transcription. The potential to reprogramme
cell lineage specification via controlling gene transcription has wide-
reaching applications for regenerative
medicine, disease modelling, and even drug screening to
name a few. The central idea is that dead-Cas9, where
the catalytic domain that cuts DNA is inactivated, is fused
with transcription activator or repressor domains. This
dCas9 fusion is targeted to promotor regions to enhance
or inhibit transcription in a reversible manner.
Much of the pioneering work has been conducted in
the Gersbach laboratory at Duke University to control
developmental events. This was first demonstrated in
2014 when Chakraborty et al39 showed that targeted
activation of the myogenic transcription factor, MyoD,
in mouse embryonic fibroblasts using gene activation
domains fused to Cas9 reprogrammed the cells to differentiate into skeletal myocytes. More recent innovations
involve repurposing type I CRISPR systems for programmable gene regulation.40
Chromosomal tracking. CRISPR can be used to dynamically track specific genomic loci. As with the examples
described above dCas9 is used but is fused to fluorescent
tags. This is similar to fluorescent in situ hybridization but
with several advantages: probes are easy to make, and labelling can be done in live cells. The gRNA and Cas9 will
bind to specific regions. Using dead-Cas9 fused to a fluorescent marker like GFP, researchers have turned dCas9
into a customizable DNA labeler compatible with fluorescence microscopy in living cells. CRISPR imaging has
numerous advantages over other imaging techniques,
including ease of implementation due to the simplicity
of gRNA design, programmability for different genomic
loci, capability of detecting multiple genomic loci, and
compatibility with live cell imaging.

CRISPR applications in basic orthopaedic
research

With this broad array of CRISPR systems that are available from gene KO and KI modifications to base editing
and epigenetic modifications, what impact have these
tools had on research into the musculoskeletal tissues
including bone, cartilage, and skeletal muscle?
Knock-out editing in vitro. Since it is relatively straightforward to KO specific genes in cell lines using the NHEJ
mechanism (Figure 1) and within the capabilities of most
orthopaedic molecular biology laboratories, most work
in the bone and joint field has been directed towards
VOL. 9, NO. 7, JULY 2020
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editing cell lines. Several examples of this are described
below.
CRISPR editing has been particularly useful for investigating the role of specific genes in osteosarcoma cells’
progression in humans cells including cell cycle genes
such as CDK11,41 factors involved in collagen biosynthesis such as GLT25D1,42 metastasis suppressor genes
in mouse cells such as Srgap2,43 and drug resistance.44
With the availability of ‘libraries’ of gene KO reagents, it
is now possible to conduct large-scale cellular screening
for novel activators/suppressors of osteosarcoma. This
is a fruitful area of research that should yield new and
exciting insights into osteosarcoma biology.
For the study of events critical for osteoclastogenesis,
mouse RAW264 cells deleted for Zscan10 and differentiated into osteoclasts by RANKL stimulation were found to
have increased osteoclast activity.45 Potential therapeutic
factors were then tested for ability to reduce osteoclastogenesis for the treatment of low bone mineral density.
The role of specific genes in chondrocyte plasticity and
regeneration has been explored. For example, deletion
of the gap junction channel protein connexin43 attenuates cellular senescence and promotes chondrocyte
regeneration in osteoarthritis.46 The power of CRISPR-
mediated gene deletion to ‘cleanly’ dissect the contribution of closely related family members to cartilage
biology was nicely demonstrated in a study of the WNT
signalling pathway members.47 Here, CRISPR was used
to delete three WNT family members independently,
thereby allowing the investigators to separately determine the contribution of each WNT factor to chondrocyte
differentiation.47
Knock-out editing in animals. The natural follow-up from
in vitro studies is to confirm findings and recapitulate human genetic variants in rodent models. Gene KO alleles
generated by CRISPR are quicker and easier to make than
‘classic’ transgenic technologies resulting in notable cost
and time savings to investigators with F1 animals at the
screening stage in as little as three months, including
construct generation time.
In the area of orthopaedic cancer, the functions of
key genes involved in osteosarcoma progression such as
Tp5348 and Era49 have been explored in mouse models
using CRISPR-mediated gene KOs, and similar KO experiments in rats have also been described.50
Correction of disease-
causing mutations in developing musculoskeletal tissues is a major research goal.
Miao et al51 corrected the Fgfr3-glycine-to-arginine mutation that causes chondrodysplasia in mice and optimized
correction by tweaking their system to maximize the efficiency of correction. CRISPR-mediated KO of the anoctamin-5 gene resulted in a phenotype that resembles the
human disease gnathodiaphyseal dysplasia, a rare skeletal disorder that is characterized by mandibular lesions,
bone fragility, and sclerosis of tubular bones.52
Many genes function in multiple tissues and physiological processes. Conditional KO mice are a useful tool
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to isolate KO effects in one tissue from effects in other
tissues. Wee et al53 generated neuropeptide Y (NPY)-
floxed (NPYflox) mice using CRISPR technology, allowing
them to study global neuropeptide Y-KO mice alongside tissue-
specific neuropeptide Y-
KO mice, thereby
providing a versatile tool for the study of neuropeptide Y
in skeletal development.
Other animal models besides mice and rats are being
used in orthopaedic research and to provide critical
supporting data initially generated in human studies.
Although lacking a weight-
bearing skeleton, zebrafish
have been used to investigate skeletal development for
several decades, and CRISPR-mediated gene editing has
been useful for the rapid generation of mutant variants
for modelling human disease and the analysis of skeletal
development. For example, whole-
exome sequencing
and linkage analysis identified three disease-
causing
missense variants in the MAPK7 gene human populations
with adolescent idiopathic scoliosis.54 CRISPR-mediated
deletion of mapk7 in zebrafish recapitulated the characteristics of idiopathic scoliosis, thereby confirming the
findings in humans. Similarly, variants in the ATP6V1H
gene are associated with short stature and osteoporosis
in humans. Loss of function mutants in the zebrafish
atp6v1h gene recapitulated the bone phenotype. The
phenotype was recovered with inhibitors of specific
matrix metalloproteinases, suggesting a new set of therapeutic targets for this disorder.55 Epigenetic regulators
such as histone deacetylases and acetyltransferases and
their role in skeletal development have also been investigated using CRISPR in zebrafish.56
The majority of genome manipulations have been
conducted in small rodents, which lack features present
in larger animal models such as Haversian canals and have
different growth plate characteristics.57,58 CRISPR genome
manipulation technologies now allow the exciting possibilities of answering orthopaedic-
related questions in
larger animal models that more closely resemble the
human skeletal system in anatomy, cellular physiology,
and the biomechanical environment. For example, deletion of DMP1 in rabbits is leading to a new understanding
of hypophosphatemic rickets Also in rabbits, deletion of
the PHEX gene, encoding a phosphate-regulating endopeptidase responsible for X-linked hypophosphatemia,
recapitulates the features of rickets in humans and will
be a good model of this disorder moving forward.59 The
identification of a rabbit ROSA26 locus will further spur
orthopaedic research in rabbits because of its use as a
safe genomic harbor suitable for nuclease-mediated gene
targeting.60
Gene knock-ins in vitro. KI models generated by the HDR
pathway are more complicated to generate than KO
models. However, compared to gene KOs, KIs provide
additional functionality such as the inclusion of protein
reporter sequences and the modelling of human mutations and potential variants (Figure 1). KIs utilize the HDR
pathway provided a segment of donor DNA is available

for insertion into the cut site. Typically, two DNA constructs are required, one to carry the gRNA and Cas sequences necessary for DNA cleavage and a second that
contains the endogenous sequence to be inserted at the
cut site. Due to this added complexity, the generation of
KI models is less efficient than that of KO models and requires more screening for the desired editing.
Bone marrow-
resident mesenchymal stem cells are
the starting point for many tissue engineering strategies
because they can be induced to differentiate into bone,
cartilage, and adipose tissue. To generate an immortalized mesenchymal stem cell line, Hu et al61 knocked-in
the SV40 sequence into the Rosa26 locus using CRISPR.
The resulting cells are immortalized and can differentiate into multiple cell types. Importantly, the immortalization is reversible via removal of the SV40 sequence
by flip recombinase (FLP)-
mediated excision. Generating a supply of reversibly immortalized mesenchymal
stem cells represents a powerful technical advance that
will have a host of tissue engineering and regeneration
applications.
Novel tools are being developed using CRISPR-based
KI approaches. For example, human-
induced pluripotent stem cells are being explored as a starting point
in tissue regeneration strategies. A COL2A1-driven green
fluorescent protein (GFP) reporter was knocked-in to a
human-induced pluripotent stem cell line using CRISPR.
This allowed the identification and purification of chondrogenic precursor cells from mixed populations of stem
cells with potential applications for tissue engineering
and in drug screens for factors that promote cartilage
production.62
There have been several reports of KI mutations
of-
function truncation mutations
in mice.63,64 Gain-
in NOTCH3 in humans result in lateral meningocele
syndrome, a rare disorder characterized by neurological
complications and osteoporosis. A stop codon cassette
was knocked-in in mice at the same location as a human
mutation and the resulting mice developed cancellous and cortical bone osteopenia without neurological
complications.63
Patients with the MAB21L2 (arginine to cysteine at
amino acid 51) mutation have eye abnormalities, skeletal
dysplasia, and intellectual disability. To understand the
pathology further, the R51C mutation was introduced
into mice by CRISPR. The Mab21l2R51C/+ mice have eyeless
phenotype and skeletal abnormalities including a joint
fusion phenotype where the humeri are fused with the
radii, and the femur is fused with the tibia. These features
model the human eye and bone phenotypes in humans.64
Knock-in large animal models. The availability of high-
quality whole genome sequences for major mammalian
species coupled with advances in reproductive biology
and embryology means that larger, more orthopaedically relevant species can now be edited using CRISPR. The
first large animal study using a KI CRISPR approach was
accomplished in sheep in 2018. Williams et al65 developed
BONE & JOINT RESEARCH
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a model of hypophosphatasia by knocking-in a known
disease-causing human mutation, resulting in an amino
acid substitution at position 359, into the sheep alkaline
phosphatase-like gene. The resulting sheep have mineralization defects consistent with human hypophosphatasia.
This landmark experiment establishes sheep as a model
for studying skeletal development and maintenance, and
paves the way for other domesticated species to be manipulated given an adequate understanding of the relevant reproductive biology.
Epigenetic regulation. Another approach targeted epigenetic marks to create a genetic switch that allows for programmable and reversible gene activation in virtually any
gene. In one early ‘proof-of-concept’ study, dCas9 was
fused to the catalytic core of the human acetyltransferase
p300 domain.66 The fusion protein catalyzes acetylation
of histone H3 lysine 27 at its target sites. This leads to
gene activation at both distal and proximal promoters.
The investigators successfully enhanced transcription of
key developmental transcription factors at both promotor sites and more distal enhancer sites. Unlike targeting epigenetic marks with drugs or inhibitors of histone
deacetylases or DNA methyltransferase, this approach
will be useful for targeting individual loci. Mochizuki et
Cas9 approach
al67 developed a combinatorial CRISPR-
for the identification of cartilage-specific Sox9 distal enhancers important for skeletal development. Using a
combination of dCas9-
mediated epigenetic silencing
and the generation of enhancer deletion mice, chromatin
immunoprecipitation, and mass spectrometry, the authors identified a far-upstream cis-element that regulates
cartilage-specific Sox9 expression and subsequent skeletal development.
As these examples demonstrate, the CRISPR toolbox
is diverse and continually expanding, allowing a large
range of genome manipulations. How are these tools
impacting orthopaedic clinical research?

7

such as chondrocytes, being refractory to transfection.
At the clinical level, the experience with targeting of
gene therapies to musculoskeletal tissues has generally
been disappointing. For example, the delivery of antisense oligonucleotide-
based drugs to skeletal muscle
for Duchenne muscular dystrophy has largely been
unsuccessful in clinical trials.68 It is noteworthy that the
FDA-
approved CRISPR-
based treatment targets retinal
tissue, which is easily accessible, and reagents can be
deposited directly onto the relevant eye structures.
With orthopaedic tissues, the extracellular matrix also
presents a significant barrier to delivery. The field must
wait for safe and effective reagent delivery methods.
Most popular approaches, including for musculoskeletal applications,69 utilize adeno-
associated viral and
lentiviral-
based methods because these viruses have
evolved machinery to efficiently infect mammalian cells.
Adeno-associated virus has been approved by the FDA for
human use, and most CRISPR-based clinical applications
will use adeno-associated virus as the delivery vector in
the foreseeable future. The drawbacks with viral vectors
include packaging capacity, immune response, and, for
lentivirus, lack of control over integration sites. This lack
of cargo-carrying capacity may be an issue for KI applications where large donor sequences to be knocked-in
are required and other vector systems that allow for the
packaging of larger cargoes need to be explored.
In the orthopaedic realm, the areas most likely to have
an impact on clinical practice are in drug discovery and
the development of large animal models. The ability to
make a single, discrete change in the genome of cells
in vitro, or model organisms in vivo, lends itself to drug
discovery. The availability of libraries containing CRISPR-
generated mutants makes it possible to conduct large-
scale genome-wide screens using phenotypic readouts at
the cellular level.70 CRISPR screening will be a powerful
tool for drug discovery.
With the goal of accurately replicating human orthopaedic
pathologies, large animal models are critically
Perspectives on CRISPR and orthopaedic
important.
The first demonstration of an orthopaedic
clinical practice
disease
model
in sheep is significant because sheep and
The use of CRISPR as a tool for genome modification is
other
large
animals
are anatomically and biomechanitransforming orthopaedic research by accelerating the
cally
more
relevant
for
answering orthopaedic research
pace of research, particularly for modelling disease-
causing mutations in vitro and in vivo. While there are questions than rodents. While a transgenic sheep core
significant problems to overcome such as off-
target will need significant resources to establish and maintain,
effects and lack of effective delivery strategies, the field one can envisage that a rich trove of findings relevant to
moves ahead with blinding speed. Despite these impres- human orthopaedic conditions would result from such a
sive developments in cell and animal models, widespread resource.
In conclusion, while the future looks good for basic
clinical use is some time off and will likely be approved on
a case-by-case basis with the need for each therapy to be orthopaedic research with CRISPR-based generation of
validated in cells, animals, and later in humans for safety. models from zebrafish to mouse and recently, rabbits
Provided off-target editing effects can be greatly mini- and sheep, at the clinical level no CRISPR-based therapies
mized or eliminated, the delivery of gene therapies to exist for orthopaedic conditions. Here, the rate-limiting
the intended cells remains a stubborn technical problem step is the lack of efficient delivery options to the relevant
and is the rate-limiting step in the development of new cells and tissues, such as bone and cartilage, which have
treatments. This is particularly true for musculoskeletal specialized extracellular matrices that are a significant
tissues where access is difficult with some cell types, barrier to delivery. These delivery limitations will need
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to be overcome if effective CRISPR-based therapies for
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